Premium
A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1
Author(s) -
Wijdenes John,
Vooijs Wim C.,
Clément Claude,
Post Jacob,
Morard Florence,
Vita Natalio,
Laurent Patrick,
Sun RenXiao,
Klein Bernard,
Dore JeanMichel
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1811.x
Subject(s) - monoclonal antibody , multiple myeloma , antibody , plasma cell , bone marrow , hybridoma technology , biology , monoclonal , antigen , microbiology and biotechnology , immunology , cd34 , stem cell
We developed a new monoclonal antibody, B‐B4, which specifically identifies human plasma cells. It strongly reacts with all multiple myeloma cell lines and with malignant plasma cells of all tumour samples of the multiple myeloma patients tested. B‐B4 does not react with any peripheral blood, bone marrow or tonsil cells. Cloning of the B‐B4 antigen reveals that the monoclonal antibody recognizes syndecan‐1. It appears that the monoclonal antibody B‐B4 is a suitable marker for human plasmocyte identification among haemopoietic cells and a useful probe for the diagnosis of haematological malignancies. Furthermore, this monoclonal antibody can be used for depletions prior to CD34 grafting.